Book Chapters

1. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci, F Akkaya S, Telatar H, Zileli T : Vascular involvement in Behcet's disease. Yearbook of Vascular Surgery, Mosby, 1993

2. Koc Y, Kansu E, Koray Z, Duru S, Batman F, Kansu T, Akkaya S, Eldem B, Sahin G, Telatar H, Zileli T: Endothelin-1,2 levels in Behcet’s Disease. In: Behcet’s disease. P. Godeau, and B. Wechsler (Editors), Elsevier, Amsterdam pp. 97-101, 1993

3. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci, F Akkaya S, Telatar H, Zileli T : Vascular involvement in Behcet's disease. Yearbook of Rheumatology, Mosby, 1994

4. Koc Y, Schenkein DP : Therapy of diffuse aggressive lymphomas. Diagnostic and Therapeutic Advances in Hematologic Malignancies (1999) Eds. Martin S. Tallmann and Leo I. Gordon, Kluwer Academic Publishers, Boston, pp. 47-73.

5. Koç Y : Akut Myeloblastik Lösemi. İç Hastalıkları Kitabı, Editör : Yasavul Ü, Hacettepe Üniversitesi Yayınları 2003, pp: 1385-92.
 
6. Koc Y : Kemik Iligi Nakli. Handbook of Oncology. NCI, 2005

7. Koc Y, Demirer T : Decision making for transplant in Mantle Cell Lymphoma. Stem Cell Transplantation. Textbook 2011 (in press)

Reviews

1. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci, F Akkaya S, Telatar H, Zileli T :Vascular involvement in Behcet's disease. J Rheumatol 1992; 19: 402-10.

2. Akpolat T, Koc Y, Gullu I, Kansu E, Kiraz S, Ersoy F, Batman F, Kansu T, Akkaya S,Telatar H, Zileli T: Familial Behcet’s disease. Eur J Med 1992; 1:391-5.

3. Koc Y, McCaffrey R: Towards specific therapy in TdT-positive leukemia: Role of cordycepin. Turk J Cancer, 1993; 23(4):167-71.

4. Koc Y, Miller KB: Management of acute myeloid leukemia and bone marrow transplantation in the elderly. Turk J Cancer, 1997; 27(4): 143-60.

5. Koc Y, Akpek G, Kansu E, et al: Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: Results of two consecutive phase II clinical studies. Cancer Investigation 1998; 16(6): 355-365.

6. Koc Y: Current management of diffuse aggressive lymphomas: Role of dose-intensive chemotherapy and peripheral stem cell/marrow transplantation. Part-I. Turk J Cancer, 1998; 28(3): 103-117.

7. Koc Y: Current management of diffuse aggressive lymphomas: Role of doseintensive chemotherapy and peripheral stem cell/marrow transplantation. Part-II. Turk J Cancer, 1998; 28(4): 151-165.

8. Koc Y, Snydman DR, Schenkein DS, Miller KB: Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Review Series in Infectious Diseases, 1999; 2:22-26.

9. Oyan B, Koc Y, Kars A, et al: Hematopoietic Stem Cell Transplantation in Hematologic Malignancies and Solid Tumors: Hacettepe University Institute of Oncology Experience. Turk J Cancer, 2003; 33(1):27-39.

10. Kansu E, Koc Y, Sullivan K : Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation. Turk J Cancer, 2003; 33(1):9-22.

11. Koç Y: Yüksek dereceli (Çok Agresif) HDL’lere Güncel Yaklaşım. Hematoloji-Onkoloji, 2002; 4:299-304.

12. Koç Y: Koloni Uyarıcı Faktörler : GM-CSF ve G-CSF. Hacettepe Tıp Dergisi, 2000; 31(2): 152-7.

13. Oyan B, Koç Y, Kansu E: Multiple Myeloma Tedavisinde Güncel Yaklaşımlar. Hacettepe Tıp Dergisi, 2003; 34(1):6-15.

14. Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E : A Randomized Trial of Continuous Infusion versus Bolus Mitoxantrone in combination with Cytarabine in Newly Diagnosed Patients with Acute Myeloblastic Leukemia. Review Article. Hematological Oncology, 2004; 22:43-53.

15. Oyan B, Koç Y. Akut myeloid lösemide transplantasyon. Türkiye Klinikleri Hematoloji 2003; 1(1).

Original Articles

1. Koc Y, Kansu E, Firat D: Comparison of indirect immunofluorescence and lymphocytotoxicity techniques in the determination of lymphocyte populations. Turk J Cancer 1986; 16(2): 81-5.

2. Kars SA, Koc Y, Ruacan S, Baltali E, Tekuzman G, Firat D: Epidermal appendage tumors in xeroderma pigmentosum. Arch Dermatol 1987; 123: 713-4.

3. Kansu E, Koc Y, Kars A, Alakavuklar M, Tekuzman G, Firat D: Mitoxantrone and cytosine arabinoside (Ara-C) in adult acute leukemia: an interim report. Journal of Chemotherapy 1989; Suppl. 4: 1268-70.

4. Anonymous.(International Study Group for Behcet’s Disease): Criteria for Diagnosis of Behcet’s Disease*. Lancet 1990; 335: 1078-80. Bu çokmerkezli uluslarası çalışmaya aktif olarak katılarak 285 Türk Behçet hastasına ait klinik verilerin “International Study Group for Behcet’s Disease” üyesi olarak Behçet Hastalığı tanı kriterlerinin belirlenmesi amacı ile kullanımı sağlandı.

5. Koc Y, Arikan R, Kolemen F, Akkaya S: Analysis of T-lymphocyte subpopulations in patients with psoriasis receiving PUVA therapy. Turk J Biol Med Sci 1991; 2(3): 181-8.

6. Koc Y, Akpek G, Akpolat T, Gullu I, Kansu E, Kiraz S, Batman F, Duru S, Kansu T, Akkaya S, Telatar H, Zileli T: Topical sucralfate therapy for oral ulcers in Behcet’s disease: a randomized double-blind study. J Dermatol Treatment 1992; 3:197-9.

7. Koc Y, Kansu E, Kars A, Ozisik Y, Tekuzman G, Baltalı E, Firat D: Continuous infusion versus bolus mitoxantrone in acute non-lymphoblastic leukemia. Journal of Chemotherapy 1993; 5(Supp 1): 672-73.

8. Tansan, Emri S, Selcuk ZT, Koc Y, Hesketh P, Baris YI: Treatment of malignant pleural mesothelioma with cisplatin, mitomycin-C and alpha interferon. Oncology, 1994; 51: 348-51

9. Foss FM, Koc Y, Stetler-Stevenson MA, Nguyen DT, O'Brien MC, Turner R, Sausville EA: Co-stimulation of cutaneous T-cell lymphoma cells by IL7 and IL2: potential autocrine or paracrine effectors in the Sezary syndrome. J Clin Oncol, 1994; 12(2): 326-35

10. Altındag Z, Sahin G, Akpek G, Koc Y, Isimer A, Kansu E, Duru S: Urinary neopterin levels as an indicator of disease activation in Behcet’s Disease. Pteridines, 1995; 6:79-83.

11. Koc Y, McCaffrey R: 2',3'-dideoxyadenosine killing of TdT-positive cells is due to a trace contaminant. Leukemia, 1995; 9: 53-57.

12. Koc Y, Urbano AG, Sweeney EB, McCaffrey R: Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells. Leukemia, 1996; 10: 1019-1024.

13. Tansan S, Koc Y, Gunhan M, Sweeney E, McCaffrey R: Augmentation of vincristine cytotoxicity by megestrol acetate in mdr positive cell lines. Cancer Chemother Pharmacol 1997; 39(4): 333-340

14. Urbano AG, Koc Y, Foss F: Arginine butyrate downregulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leukemia 1998; 12:930-936

15. Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E: Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer, 1999; 85:608-15.

16. Engels EA, Ellis C, Supran SE, Schmid CH, Barza M, Schenkein DP, Koc Y, Miller K, Wong JB: Early infection in bone marrow transplantation: a quantitative study of clinical factors that affect risk. Clinical Infect Dis, 1999; 28:256-66.

17. Jabro G, Koc Y, Miller K, Boyle T, Ravalese J, Schenkein D, Sprague K, Berkman E: The role of splenic irradiation prior to bone marrow transplantation for chronic myeloid leukemia. Biol of Blood Marrow Transplant 1999; 5(3):173-9.

18. Koc Y, Miller K, Schenkein DP, Griffith J, Akhtar M, DesJardin J, Snydman DR: Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors and clinical outcome. Biol Blood Marrow Transplant, 2000; 6:44-49.

19. Schenkein DP, Koc Y, Alcindor T, Stadtmauer EA, Miller KB, Cooper BW, Partridge AH, Lazarus HM: Treatment of primary resistant or relapsed multiple myeloma with high-dose chemotherapyl, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor. Biol of Blood Marrow Transplant 2000; 6:448-55.

20. Abali H, Oyan B, Koc Y, Kars A, Barista I, Uner A, Turker A, Demirkazik F, Tekin F, Tekuzman G, Kansu E : IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. Am J Clin Oncol. 2005 Jun;28(3):264-9.

21. Oyan B, Koc Y, Evren Ozdemir, Ayse Kars, Alev Turker, Gulten Tekuzman, Emin Kansu : Ifosfamide, Idarubicin, and Etoposide in Relapsed/Refractory Hodgkin Disease or Non-Hodgkin Lymphoma: A Salvage Regimen with High ResponseRates before Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2005; 11:688-697.

22. Abali H, Oyan B, Koc Y, Kars A, Barista I, Uner A, Turker A, Demirkazik F, Tekin F, Tekuzman G, Kansu E : IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. Am J Clin Oncol 2005 Jun;28(3):264-9.

23. Miller K, Schenkein D, Jabro G, Koc Y, Boyle, Ravalese J, Wazer D: Response to Gratwohl et al. Biol Blood Marrow Transplant, 2000; 6(2):213.

24. Demirkazık A, Güllü İ, Baltalı E, Kars A, Tekuzman G, Koç Y, Güler N, Barışta İ, Fırat D: L-Phenylalanine mustard (L-PAM) use as adjuvant chemotherapy in operable (Stage II-IIIA) breast cancers. Türk Hematoloji Onkoloji Dergisi, 1991; 1(3):133-136.

25. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.:High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma. 2006 Aug;47(8):1545-52.

26. Ozdemir E, Koc Y, Kansu E.: Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hematol. 2006 Jun;81(6):474. No abstract available.

27. Oyan B, Koc Y, Emri S, Kansu E: Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis. Med Oncol. 2006;23(1):125-9.

28. Oyan B, Koc Y: Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy? Ann Oncol. 2006 Feb;17(2):349-50. Epub 2005 Sep 15.

29. Oyan B, Koc Y, Kansu E: Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase. Int J Hematol. 2005 Feb;81(2):155-8.

30. Yirmibescik S, Senkal V, Kalaycı G, Aktas S, Aydin D, Sönmezoglu M, Kocagoz S, Oyan B, Koc Y: Hematopoietic Stem Cell Transplantation for Hematological diseases at Yeditepe University Hospital.

Biol Blood Marrow Transplant 2007 13(2, Suppl 2) : 94.

31. Uckan-Cetinkaya D, Unal S, Cetin M, Sarikabadayi U, Aktas D, Koc Y: Splenectomy status of the patient may have impact on response to donor lymphocyte infusions. Leukemia. 2007 Sep;21(9):2049-50.

Case Reports

1. Koc Y, Kars SA, Kansu E, Tekuzman G, Baltali E, Firat D: Aplastic anemia in a patient receiving tamoxifen. Int J Hematol 1991; 54: 263-4.

2. Koc Y, Kars SA, Kansu E, Firat D: Acute lymphoblastic leukemia in breast cancer: Report of a case. Turk J Cancer, 1991; 21:125-9.

3. Koc Y, Snydman DR, Schenkein DP, Miller KB: Vancomycin-resistant enterococcal infections in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 1998; 22(2):207-209.

4. Koç Y, Oyan B, Akhtar MS, Schenkein DP, Miller KB: Successful allogeneic marrow transplantation from donors with hematologic malignancies. Turk J Cancer, 2004; 34(3):118-121.

5. Oyan B, Koc Y, Kansu E: Successful Salvage with High-Dose Sequential Chemotherapy Coupled with in vivo Purging and Autologous Stem Cell Transplantation in 2 Patients with Primary Refractory Mantle Cell Lymphoma Presenting in the Leukemic Phase. Int J Hematol 2005; 81(2): 155-8.

6. Oyan B, Koc Y, Emri, Kansu E : Improvement of Chronic Pulmonary Graft-Vs-Host Disease Manifesting as Bronchiolitis Obliterans Organizing Pneumonia Following Extracorporeal Photopheresis. Medical Oncology, vol. 22,   2005

Abstract, Poster and Presentations

1. Kansu E, Koc Y, Kars A, Alakavuklar M, Tekuzman G, Firat D: Mitoxantrone and cytosine arabinoside (Ara-C) in adult acute leukemia: an interim report. VIth Mediterranean Congress of Chemotherapy, Taormina-Italy, May 22-27, 1988

2. Kansu E, Koc Y, Kars SA, Ozisik Y, Tekuzman G, Baltali E, Firat D: Mitoxantrone in acute leukemia: an interim report.

Vth meeting of the Mediterranean Blood Club, Antalya, Sep 21-24 1990; no.99

3. Kansu E, Koc Y, Kars SA, Ozisik Y, Tekuzman G, Baltali E, Firat D: Continuous infusion versus bolus mitoxantrone in acute non-lymphoblastic leukemia. XIth meeting of the International Society of Hematology, European and African Division, Basel-Switzerland, Aug. 31 Sep 6, 1991.

4. Berk V, Kansu E, Koc Y, Firat D: Relationship of serum immune-complex, immunoglobulin and complement levels with therapy in cancer patients. (abstract) IXth National Cancer and VIth Pediatric Tumors Congress, Izmir-Turkey, Jun 2-7 1991

5. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Batman F, Telatar H, Kansu T, Zileli T: Vascular involvement in Behcet’s disease: Hacettepe University experience. IInd Mediterranean Congress of Angiology, Antalya-Turkey, Sep 16-21, 1990; no.162

6. Akpek G, Ozmen M, Sozen T, Batman F, Usman A, Akhan O, Koc Y: The effect of somatostatin on gallbladder volume in patients with diabetes mellitus. World Diabetes Day and National Diabetes Congress, Silivri-Istanbul, Turkey 27-29 May 1991, p. 96-7

7. Okur H, Kansu E, Canpinar H, Koc Y, Firat D: In vitro myeloid stem cell colony assay in patients with acute myeloblastic leukemia. XXIIth National Hematology Congress, Istanbul-Turkey, Oct 21-25, 1991

8. Kansu E, Koc Y, Kars SA, Ozisik Y, Tekuzman G, Baltali E, Firat D: Continuous infusion versus bolus mitoxantrone in acute nonlymphoblastic leukemia. XXIIth National Hematology Congress, Istanbul-Turkey, Oct 21-25, 1991

9. Kansu E, Koc Y, Kars SA, Ozisik Y, Tekuzman G, Baltali E, Firat D: Mitoxantrone, vincristine and prednisone therapy in acute lymphoblastic leukemia. XXIIth National Hematology Congress, Istanbul-Turkey, Oct 21-25, 1991

10. Kansu E, Canpinar H, Koc Y, Tekuzman G, Baltali E, Firat D: Immunophenotypic analysis of acute and chronic leukemias using flow cytometry. XIIIeme Journess de Cancerologie Franco-Turque, Ankara-Turkey, Sep 26-27, 1991

11. Canpinar H, Koc Y, Kansu E: Immunophenotypic analysis of peripheral blood lymphocytes in healthy adults using flow cytometry. XIIth National Immunology Congress, Istanbul-Turkey, Nov 11-15, 1991

12. Koc Y, Kansu E, Kars SA, Ozisik Y, Tekuzman G, Baltali E, Firat D: Continuous infusion versus bolus mitoxantrone in acute non-lymphoblastic leukemia. VIIIth Mediterranean Congress of Chemotherapy, Athens-Greece, May 24-29 1992

13. Koc Y, Chu CK, Beardsley GP, and McCaffrey RP: Cordycepin is selectively cytotoxic for TdT-positive cells. Blood 1992; 80(10, Suppl 1):451a.

14. Foss F, Nguyen D, Koc Y, Vosburgh E and McCaffrey RP: IL7 induces IL2R expression on human leukemia cells. Blood 1992; 80(10, Suppl 1):34a.

15. Akpek G, Koc Y, Kansu E, Kars A, Guler N, Tekuzman G, Baltali E, Oguz AK, Canpinar H, Firat D: Results of mitoxantrone-vincristine-prednisone chemotherapy in patients with newly diagnosed acute lymphoblastic leukemia. 23rd National Hematology Congress, Istanbul-Turkey, Oct 1-5, 1993

16. Foss F, Koc Y, Nguyen D, Turner R, McCaffrey R, Sausville E: IL-7 regulates proliferation and IL2 receptor expression in Mycosis Fungoides and the Sezary syndrome. Am Soc Clin Oncol, 1993; 12:122.

17. Koc Y, Chu CK, Beardsley GP, McCaffrey R: Cordycepin selectively kills TdTpositive cells. Am Soc Clin Oncol, 1993; 12:119.

18. Tansan S, Koc Y, Gunhan M, Sweeney E, McCaffrey R: Unique augmentation of vincristine cytotoxicity by megestrol acetate in mdr positive cell lines. Am Soc Clin Oncol, 1993; 12:119.

19. Koc Y, Urbano A, Sweeney E, Foss F, McCaffrey R: Cordycepin activates an apoptotic cascade in TdT-positive leukemia cells. Blood 1993; 82 (Suppl 1): 115a

20. Foss F, Koc Y, Sanders D, O’Brien M, Faller D, McCaffrey R: Biomodulatory effects of butyric acid derivatives on leukemia and lymphoma cells. Blood 1993; 82 (Suppl 1): 564a

21. Koc Y, Urbano A, Sweeney E, Foss F, McCaffrey R: Induction of apoptosis in TdTpositive leukemia/lymphoma cells by cordycepin. Am Soc Clin Oncol, 1994; 13:126.

22. Emri S, Koc Y, O’Brien MC, Sanders D, Tansan S, Foss F: Taxol and arginine butyrate exert additive anti-proliferative effects on human mesothelioma cells. Am Soc Clin Oncol, 1994; 13:130.

23. Foss F, O’Brien M, Koc Y, Lyons K, Russell L, McCaffrey R, Sanders D: Effects of arginine butyrate on growth and chemosensitivity of human epithelial neoplasms. Am Soc Clin Oncol, 1994; 13:162.

24. Akpek G, Koc Y, Kansu E, Kars A, Guler N, Tekuzman G, Baltali E, Oguz AK, Canpinar H, Firat D: Mitoxantrone, vincristine and prednisone combination chemotherapy in patients with newly diagnosed acute lymphoblastic leukemia. Presented in XVIth International Cancer Congress, New Delhi, 1994

25. Koc Y, Cotter T, McCaffrey R: Cordycepin-induced apoptotic cell death in TdTpositive leukemia/lymphoma cells is associated with nitric oxide formation. Blood, 1994; 84 (Suppl 1): 141a

26. Koc Y, McCaffrey R, Foss F: Arginine butyrate induces apoptosis in selected hematopoietic tumor cell lines. Blood, 1994; 84 (Suppl 1): 285a

27. Koc Y : Effective treatment of human TdT+ pre-B acute lymphoblastic leukemia with 3’-deoxyadenosine and coformycin in SCID-mice. Hematology-Oncology Fellowship Program in Hematologic Malignancies, Amelia Island, Florida , Oct 30-Nov 1, 1997.

28. Jabro G, Koc Y, Miller K, Boyle T, Ravalese J, Schenkein D, Sprague K, Berkman E: The role of splenic irradiation prior to bone marrow transplantation for chronic myeloid leukemia. Blood, 1997; 90 (Suppl 1): 375a

29. Koc Y, Miller K, Schenkein D, Sprague K, Berkman E, DesJardin J, Snydman D: Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, clinical outcome and antiviral prophylaxis. Blood, 1997; 90 (Suppl 1): 543a

30. Koc Y, Miller K, Schenkein D, Sprague K, Berkman E: Comparison of standard and short course methotrexate in combination with adjusted dose continuous infusion cyclosporin-A to prevent acute graft-versus-host disease. Blood, 1997; 90 (Suppl 1): 370b

31. Koc Y, Kansu E, Kars A, Akpek G, Tekuzman G, Firat D: A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in previously untreated patients with acute myeloblastic leukemia. Blood, 1998; 91 (Suppl 1): 3930

32. Koc Y, K. Sprague, K, Schenkein DP, Berkman E, Miller KB: Treatment of relapsed/refractory or secondary acute leukemias with allogeneic bone marrow transplantation. Blood, 1998; 91 (Suppl 1): 4513

33. Koc Y, Miller KB, Schenkein DP, DesJardin J, Snydman DR: Ganciclovir administration for cytomegalovirus infection prophylaxis delays onset of varicella zoster virus reactivation in allogeneic bone marrow transplant recipients. Blood, 1998; 91 (Suppl 1): 1150

34. Schenkein DP, Koc Y, Alcindor T, Stadtmauer EA, Miller KB, Lazarus HM: Highdose chemoradiotherapy and peripheral stem cell rescue for primary resistant or recurrent myeloma: long-term follow-up of phase I-II study. Blood, 1998; 91 (Suppl 1): 2736

35. Roberts T, Koc Y, Sprague K, Grodman H, Mogavero D, Berkman E, Schenkein D, Miller KB: Second allogeneic marrow transplant after relapse of hematologic malignancies following first autologous or allogeneic bone marrow transplant. Blood, 1999 94: (Suppl 1): 4928

36. Schenkein DP, O'Connor CE, Morelli JA, Berkman E, Erban JK, Sprague KA, Koc Y, Terrin C, Miller KB: A randomized trial of 2 different priming methods for stem cell mobilization in patients with relapsed Hodkin’s disease and Non-Hodgkins Lymphoma. Blood, 1999 94: (Suppl 1): 1460

37. Roberts T, Koc Y, Sprague K, Grodman H, Berkman E, Schenkein D, Miller KB: Mycophenolate mofetil (MMF) for the treatment of chronic graft versus host disease (cGVHD) of the liver. Blood, 1999 94: (Suppl 1): 697

38. Roberts T, Koc Y, Sprague K, Grodman H, Berkman E, Schenkein D, Miller KB: Outcome of patients with primary refractory Non-Hodgkins lymphoma (NHL) and Hodgkin’s disease (HD) treated with allogeneic or autologous bone marrow transplant (BMT). Blood, 1999 94: (Suppl 1): 736

39. Oyan B, Koc Y, Kars A, Turker A, Guc D, Zorlu F, Uner A, Ruacan S, Yigitbas E, Tekin F, Uzun O, Tekuzman G, Kansu E : Rational Use of Hematopoietic Stem Cell Transplantation and Thalidomide to Achieve Molecular Remission in Myeloma. XVIIth Meeting of the International Society of Hematology, Graz, Austria, Sep 10th, 2003, Oral Presentation.

40. Elkıran T, Oyan B, Koc Y, Kars A, Turker A, Tekin F, Cetinkaya Y, Uzun O, Akova M, Unal S, Tekuzman G, Kansu E : Infectious Complications During Non-Myeloablative Allogeneic Transplantation. XVIIth Meeting of the International Society of Hematology, Graz, Austria, Sep 9th, 2003, Oral Presentation.

41. Koc Y: Lenfomada Yüksek Doz Tedavi, Otolog, Allojeneik, Non-myeloablatif Kök Hücre Transplantasyonu. XV. Ulusal Kanser Kongresi, 26 Nisan 2003, Kemer, Antalya, Konferans.

42. Abali H, Koc Y, Oyan B, Tekin F, Tekuzman G, Kansu E: IIVP Salvage Regimen Induces High Response Rates in Patients with Relapsed HD or NHL prior to Autologous HSCT. Blood, 2002; 100 (Suppl 1):4714

43. Oyan B, Koc Y, Kansu Y: High-Dose Sequential Chemotherapy in Relapsed or Refractory Hodgkin's and Non-Hodgkin's Lymphoma. Blood, 2002; 100 (Suppl 1):5462

44. Oyan B, Koc Y, Tekin F, Kansu E: Successful Salvage with High-Dose Sequential Chemotherapy Coupled with Autologous PBSCT and In Vivo Purging with Rituximab in Patients with Primary Refractory Mantle Cell Lymphoma Presenting in Leukemic Phase. Blood, 2002; 100 (Suppl 1):5463

45. Rocha V, Labopin M, Koc Y, Finke J, Gratwohl A, Fassas A, Schwaren A, Schaeffer U, Gluckman E, Frassoni F: Risk Factors for Chronic GvHD after Allogeneic Peripheral Blood Stem Cell Transplants in Patients with Acute Leukemia. Blood, 2002; 100 (Suppl 1):1671

46. Rocha V, Labopin M, Koc Y, Finke J, Gratwohl A, Fassas A, Schwaren A, Schaeffer U, Gluckman E, Frassoni F: Risk Factors for Chronic GvHD after Allogeneic Peripheral Blood Stem Cell Transplants in Patients with Acute Leukemia.Bone Marrow Transplantation, 2002; 29(S2):S73.

47. Kav S, Koc Y, Kansu E : Problems Encountered During IFN-alfa Therapy Following Autologous Stem Cell Transplantation: A Preliminary Report. Bone Marrow Transplantation, 2002; 29(S2):S261.

48. Abali H, Karaoglu A, Tekuzman G, Koc Y, Kansu E: IIVP Regimen for Salvage Therapy in Patients with Relapsed Lymphoma Prior to Autologous Stem Cell Transplantation. Blood, 2002; 100(Suppl 1):5337.

49. Koc Y: Current Concepts in the Collection and Use of Hematopoietic Stem Cells in the Management of Patients with Hematologic Cancer. Biomed 2002, IXth International Symposium on Biomedical Science and Technology. September 19-22, Antalya, Turkey, Conference.

50. Oyan B, Koc Y, Kars A, Turker A, Tekuzman G, Kansu E: Achieving High Remission Rate with Use of Autologous HSCT, Thalidomide Maintenance and Non-Myeloablative Allogeneic HSCT in Patients with Multiple Myeloma. Blood, 2003; 102(Suppl 1): 5288.

51. Oyan B, Koc Y, Ozdemir E, Kansu E: High-dose Sequential Chemotherapy coupled with Autologous PBSCT and in-vivo purging with Rituximab in patients with relapsed/refractory or high-risk B-cell NHL. Bone Marrow Transplantation, 2005; 35 (Suppl 2): S385 (R250).

52. Özdemir E, Koç Y, Oyan B, Kansu E: Myeloablatif olmayan allojeneik kök hücre nakli (NST): Hacettepe Onkoloji Enstitüsü deneyimi. XXXI. Ulusal Hematoloji Kongresi 23-28 Eylül 2004, Belek, Antalya, p. 39. Turk J Hematol 2004; 21(3): A5. (Sözel sunum)

53. Oyan B, Koc Y, Ozdemir E, Kansu E: Relaps/Refrakter Hodgkin Lenfoma (HL) ve Hon-Hodgkin Lenfoma (NHL)’da kurtarma tedavisi olarak IIVP rejimi ile yüksek cevap oranları. XXXI. Ulusal Hematoloji Kongresi 23-28 Eylül 2004, Belek, Antalya, p. 43 Turk J Hematol 2004; 21(3): A17. (Sözel sunum)

54. Oyan B, Koc Y, Ozdemir E, Kansu E: Multipl Myelomda Otolog Kök Hücre Nakli (KHN), Nonmyeloablatif Allojenik Kök Hücre Nakli (NST), Talidomid ve Bortezomib’in rasyonel kullanımı ile remisyon sağlanması. XXXI. Ulusal Hematoloji Kongresi 23-28 Eylül 2004, Belek, Antalya, p.66. Turk J Hematol 2004; 21(3): A66. (Sözel sunum).

55. Oyan B, Tekuzman G, Barista I, Ozisik Y, Kars A, Turker A, Yalcin S, Guler N, Koc Y, Kansu E: Prognostic Factors and Outcome in 306 consecutive patients with Diffuse Large B-Cell Lymphoma (DLBCL). Ann Oncol, 2004; 15 (Suppl 3) 576T

56. Koç Y : Antiviral tedavi ve profilaksi. 3. Febril Nötropeni Mezuniyet Sonrası Eğitim Kursu, 27-29 Şubat 2004, Bilkent Konferans Merkezi, Ankara. Konferans.

57. Koç Y : Kemoterapi ve Radyoterapi Toksisitesi, Etkileşimler ve İlaç Monitorizasyonu. Kan ve Kemik İliği Transplantasyon Kursu. Türk Hemetoloji Derneği Transplantasyon Alt Komitesi. 17-18 Ocak 2004, Çeşme-İzmir. Konferans.

58. Şahin GÖ, Koç Y, Göker H, Kansu E, Şardan YÇ, Uzun Ö, Ünal S, Akova M: Kök hücre nakli (KHN) yapılan hastalarda febril nötropenik atakların değerlendirilmesi : Hacettepe deneyimi. 3. Febril Nötropeni Mezuniyet Sonrası Eğitim Kursu, 27-29 Şubat 2004, Bilkent Konferans Merkezi, Ankara. Sözel sunum.

59. Oyan B, Koc Y, Ozdemir E, Kansu E : High-dose sequential chemotherapy (HDSC) In support of Autologous Stem Cell Transplantation (ASCT) in patients with relapsed/refractory Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). Blood, 2004; 104(11):5231

60. Koc Y, Ozdemir E, Oyan B, Kansu E : Nonmyeloablative allogeneic stem cell transplantation: Hacettepe University Institute of Oncology experience. Blood, 2004; 104(11):5155

61. Oyan B, Koç Y, Ozdemir E, Kansu E: Relaps refrakter Hodgkin Lenfoma (HL) ve Non-Hodgkin Lenfoma (NHL) hastalarında otolog kök hücre nakli (OKHN) eşliğinde yüksek doz ardışık kemoterapi (YDAK) XXXI. Ulusal Hematoloji Kongresi 23-28 Eylül 2004, Belek, Antalya, p.150 Turk J of Hematol 2004; 21(3): A295. (Poster sunumu).

62. Koç Y: Uluslararası akreditasyon incelikleri (JACIE) : Klinik ve laboratuvar özellikler. XXXI. Ulusal Hematoloji Kongresi, Erişkin kemik iliği transplantasyonu alt komitesi toplantı programı, 23-28 Eylül 2004, Belek, Antalya. Konferans.

63. Akın A, Demirkazık F, Gulsun M, Koc Y: CT findings of pulmonary infections ın the immunocompromised patients. European Congress of Radiology, 24 Eylül 2004, Neutorgasse 9/2a, AT-1010 Vienna, Austria. Sözel sunum.

64. Y Koç: Lenfomada sitogenetik ve moleküler genetik özellikler. Hacettepe Sürekli Tıp Eğitimi (STE) : Lenfoma: Tanıdan Tedaviye. 5 Mart 2004, Hacettepe Üniversitesi Kültür ve Kongre Merkezi. Konferans.

66. Koç Y: Non-myeloablatif hematopoietik kök hücre naklinde yenilikler. Onkoloji 2005, 25-26 Kasım 2005, Bilkent-Ankara. Konferans.

67. Koc Y: Principles and Applications of Photopheresis. XVth Congress of the Interdisciplinary European Society for Haemapheresis and Haemotherapy (ESFH) and 2nd National Congress of Haemapheresis, October 5-9, 2005, Antalya-Turkey. Konferans.